What Outcomes May Look Like With Spravato for Treatment-Resistant Depression at Healing and Psychiatry in Flagstaff, AZ

For individuals living with treatment-resistant depression (TRD), finding an effective path forward can feel overwhelming. When standard antidepressants have not provided adequate relief, newer treatment options like Spravato (esketamine nasal spray) offer a reason for cautious optimism. If you have been researching the efficacy comparison of Spravato vs. IV ketamine for depression, you are far from alone – it is one of the most common questions patients and their families ask when exploring next steps. At Healing and Psychiatry in Flagstaff, AZ, our team is committed to helping patients understand what Spravato may offer and what realistic outcomes can look like within a structured, professionally supervised treatment environment.

Understanding Spravato: What It Is and How It Works

Spravato is the brand name for esketamine, a nasal spray derived from ketamine that received FDA approval specifically for treatment-resistant depression. Unlike traditional antidepressants that primarily target serotonin, norepinephrine, or dopamine pathways, Spravato works on the glutamate system – the brain’s most abundant excitatory neurotransmitter. This mechanism of action is believed to help restore synaptic connections in brain areas affected by chronic depression, potentially offering relief where other medications have not.

Spravato is administered in a certified healthcare setting under direct clinical supervision. At Healing and Psychiatry, patients receive their treatment in a controlled, comfortable environment in Flagstaff, where they are monitored for a minimum of two hours following each session. This protocol is part of the FDA’s Risk Evaluation and Mitigation Strategy (REMS), which ensures patient safety throughout the treatment process.

How Spravato Differs From IV Ketamine

One of the most frequently asked questions among patients considering ketamine-based therapies involves the efficacy comparison of Spravato vs. IV ketamine for depression. While both treatments share a pharmacological foundation, there are meaningful distinctions. Spravato (esketamine) is specifically the S-enantiomer of ketamine, delivered as a nasal spray, while IV ketamine involves intravenous administration of racemic ketamine. A key benefit of Spravato is its FDA-approved status for TRD, which means it has undergone rigorous clinical trials demonstrating its safety and efficacy for this specific patient population. IV ketamine, while used clinically, is typically administered off-label for depression. Both approaches have shown promise, but the regulatory pathway behind Spravato provides an additional layer of clinical validation that many patients and providers find reassuring.

Potential Benefits of Spravato for Treatment-Resistant Depression

Patients at Healing and Psychiatry in Flagstaff often want to know what tangible benefits they might experience with Spravato. While individual outcomes vary and no treatment works identically for every person, clinical research and patient experiences in 2026 continue to highlight several potential advantages.

Faster Onset of Symptom Relief

One of the most notable potential benefits of Spravato is the speed at which some patients begin to notice changes. Traditional antidepressants may take four to six weeks or longer before patients experience meaningful improvement. In contrast, some individuals treated with Spravato have reported improvement in depressive symptoms within hours to days of their initial sessions. This faster onset may be particularly meaningful for patients who have been struggling with severe, persistent depression and are seeking more timely relief.

A New Mechanism for Those Who Have Not Responded to Other Medications

By definition, treatment-resistant depression means that at least two adequate trials of different antidepressant medications have failed to produce satisfactory results. Spravato’s glutamate-based mechanism of action represents a fundamentally different approach. For patients who have cycled through multiple SSRIs, SNRIs, or other medication classes without adequate improvement, this alternative pathway may offer new possibilities. Healing and Psychiatry works closely with each patient to evaluate whether Spravato may be an appropriate addition to their overall treatment plan.

Structured, Supervised Treatment Environment

Another benefit that patients frequently appreciate is the structured nature of Spravato treatment. Because sessions take place in a clinical setting with professional oversight, patients are continuously monitored for any side effects, including temporary increases in blood pressure, dissociation, or sedation. This supervised model helps ensure both safety and accountability throughout the treatment course. At Healing and Psychiatry, the clinical team provides personalized attention during each visit, helping patients feel supported and informed at every stage.

Potential to Complement Existing Treatment Plans

Spravato is typically prescribed alongside an oral antidepressant, which means it is designed to work within a broader treatment framework rather than as a standalone solution. This integrative approach may enhance overall outcomes for patients who have achieved partial but incomplete responses to their current medications. The combination strategy reflects an evolving understanding in psychiatry that treatment-resistant depression often benefits from a multimodal approach.

What the Treatment Timeline May Look Like

Understanding the expected treatment timeline can help patients set realistic expectations. The standard Spravato protocol involves three phases:

• Induction Phase (Weeks 1–4): Patients typically receive Spravato twice per week. This initial phase is designed to establish the therapeutic foundation and allow the clinical team to assess the patient’s response and tolerability.
• Maintenance Phase (Weeks 5–8): Sessions are generally reduced to once per week. During this phase, the team at Healing and Psychiatry evaluates how the patient is responding and makes any necessary adjustments.
• Long-Term Maintenance (Week 9 and beyond): Depending on each patient’s progress, sessions may be further reduced to once every one to two weeks. The goal is to identify the minimum effective frequency that supports sustained improvement.

It is important to note that not every patient will follow this exact timeline, and the clinical team at Healing and Psychiatry tailors the schedule based on individual progress and needs. Some patients may experience noticeable benefits early in the process, while others may require a longer course before meaningful changes become apparent.

Realistic Expectations: What Outcomes Research Suggests in 2026

As of 2026, the body of evidence supporting Spravato for treatment-resistant depression continues to grow. Clinical trials and real-world data have shown that a significant proportion of patients experience measurable reductions in depressive symptoms, as assessed by standardized tools such as the Montgomery-Åsberg Depression Rating Scale (MADRS). However, outcomes are not universal, and some patients may experience partial improvement rather than full remission. This is why ongoing evaluation and open communication with the treatment team are essential.

When patients at Healing and Psychiatry ask about the efficacy comparison of Spravato vs. IV ketamine for depression, the clinical team provides an honest, evidence-based perspective. Both treatments have demonstrated potential for reducing depressive symptoms, but Spravato’s FDA approval for TRD, its standardized dosing protocol, and its established safety monitoring framework are distinct advantages that inform treatment decisions. The best choice depends on a range of individual factors, including medical history, treatment goals, and the patient’s unique clinical profile.

Who May Be a Good Candidate for Spravato

Spravato may be appropriate for adults who have been diagnosed with treatment-resistant depression – meaning they have not achieved adequate improvement with at least two different antidepressant medications taken at appropriate doses for sufficient durations. Candidates are evaluated carefully to ensure they do not have contraindications, such as certain vascular conditions or a history of aneurysmal disease.

At Healing and Psychiatry, every prospective Spravato patient undergoes a thorough clinical assessment before beginning treatment. This evaluation considers the patient’s full psychiatric and medical history, current medications, and overall treatment goals. The team believes that informed, collaborative decision-making is fundamental to achieving the best possible outcomes.

Why Patients in Flagstaff Choose Healing and Psychiatry

Flagstaff residents and individuals throughout Northern Arizona seeking advanced options for treatment-resistant depression have access to Spravato treatment at Healing and Psychiatry. The practice combines clinical expertise with a patient-centered philosophy, ensuring that every individual who walks through the door is treated with respect, transparency, and genuine care. The team understands that living with TRD can be exhausting and isolating, and they are dedicated to providing a treatment experience that is both clinically rigorous and compassionate.

For those who have been weighing the efficacy comparison of Spravato vs. IV ketamine for depression, Healing and Psychiatry offers the opportunity to discuss both options with a knowledgeable clinical team that can provide personalized guidance based on the latest evidence and each patient’s unique situation.

Taking the Next Step Toward Treatment

If you or someone you care about has been living with treatment-resistant depression and has not found adequate relief through traditional medications, Spravato may represent a meaningful option worth exploring. While no treatment can guarantee specific outcomes, the growing body of clinical evidence and the experiences of many patients suggest that Spravato has the potential to make a real difference in quality of life.

Healing and Psychiatry in Flagstaff, AZ welcomes patients who are ready to learn more about what Spravato treatment may offer. We encourage you to reach out to our team to schedule a consultation and discuss whether this treatment may be right for you. Every journey toward improved mental health begins with a conversation, and our team is here to listen, educate, and support you through the process.